155 related articles for article (PubMed ID: 23505902)
1. Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany.
Vamvakas EC; Hitzler WE
Clin Lab; 2013; 59(1-2):1-22. PubMed ID: 23505902
[TBL] [Abstract][Full Text] [Related]
2. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
3. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
Vamvakas EC
Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
[TBL] [Abstract][Full Text] [Related]
4. Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany.
an der Heiden M; Ritter S; Hamouda O; Offergeld R
Vox Sang; 2015 Feb; 108(2):123-30. PubMed ID: 25335096
[TBL] [Abstract][Full Text] [Related]
5. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
Pietersz RN
Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
[TBL] [Abstract][Full Text] [Related]
6. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
[TBL] [Abstract][Full Text] [Related]
7. Use of random versus apheresis platelet concentrates.
Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
[TBL] [Abstract][Full Text] [Related]
8. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis.
Thiele T; Alt-Mayer T; Greinacher A; Bux J
Vox Sang; 2016 Nov; 111(4):350-356. PubMed ID: 27432635
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA.
McCormick MK; Dockter J; Linnen JM; Kolk D; Wu Y; Giachetti C
J Clin Virol; 2006 Jul; 36(3):166-76. PubMed ID: 16427802
[TBL] [Abstract][Full Text] [Related]
10. A critical comparison of platelet preparation methods.
Vassallo RR; Murphy S
Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
[TBL] [Abstract][Full Text] [Related]
11. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
Shang G; Seed CR; Wang F; Nie D; Farrugia A
Transfusion; 2007 Mar; 47(3):529-39. PubMed ID: 17319836
[TBL] [Abstract][Full Text] [Related]
12. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
13. Platelet concentrates, from whole blood or collected by apheresis?
van der Meer PF
Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
[TBL] [Abstract][Full Text] [Related]
14. Relative risk of reducing the lifetime blood donation deferral for men who have had sex with men versus currently tolerated transfusion risks.
Vamvakas EC
Transfus Med Rev; 2011 Jan; 25(1):47-60. PubMed ID: 21134626
[TBL] [Abstract][Full Text] [Related]
15. Sterility screening of platelet concentrates: questioning the optimal test strategy.
Dreier J; Störmer M; Pichl L; Schottstedt V; Grolle A; Bux J; Kleesiek K
Vox Sang; 2008 Oct; 95(3):181-8. PubMed ID: 19121182
[TBL] [Abstract][Full Text] [Related]
16. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
17. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations.
Koppelman MH; Assal A; Chudy M; Torres P; de Villaescusa RG; Reesink HW; Lelie PN; Cuypers HT
Transfusion; 2005 Aug; 45(8):1258-66. PubMed ID: 16078910
[TBL] [Abstract][Full Text] [Related]
18. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
Lozano ML; Rivera J; Vicente V
Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
[TBL] [Abstract][Full Text] [Related]
19. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
Schrezenmeier H; Seifried E
Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
[TBL] [Abstract][Full Text] [Related]
20. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.
Seed CR; Kiely P; Keller AJ
Intern Med J; 2005 Oct; 35(10):592-8. PubMed ID: 16207258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
